Thomas Appio to lead Bausch + Lomb on an interim basis
Bausch + Lomb appointed Thomas Appio interim CEO after Brent Saunders’ departure and signaled a 2026 adjusted EBITDA guidance increase, with details due Oct. 28.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Bausch + Lomb has installed board chairman Thomas Appio as interim chief executive, effective immediately. Brent Saunders, who had led the company since 2023, will leave after reaching an agreement with the board, Seeking Alpha reported. Appio has run parent company Bausch Health since 2022 and has chaired Bausch + Lomb’s board since August 2026.
Dow Jones Newswires said Bausch + Lomb now anticipates raising its full-year 2026 adjusted EBITDA outlook. Seeking Alpha reported that Bausch + Lomb and Bausch Health expect a higher figure excluding acquired in-process research and development costs. The companies are in a disclosure blackout and will give further information when third-quarter results are released on Oct. 28.
why it matters
The leadership transition makes the Oct. 28 results more important, as investors will receive details on both Appio’s interim role and the expected financial-guidance revision.
instruments
sources
- Bausch + Lomb Names Appio as Interim CEO — Dow Jones Newswires, 12 October 2026 at 11:10 UTC
- Bausch + Lomb names Thomas Appio interim CEO, signals guidance hike — Seeking Alpha, 12 October 2026 at 11:35 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗